Your browser doesn't support javascript.
loading
α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model.
So, Raphaella W L; Amano, Genki; Stuart, Erica; Ebrahim Amini, Aeen; Aguzzi, Adriano; Collingridge, Graham L; Watts, Joel C.
Affiliation
  • So RWL; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Amano G; Department of Biochemistry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Stuart E; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Ebrahim Amini A; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Aguzzi A; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Collingridge GL; Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Watts JC; Institute of Neuropathology, University of Zurich, Zurich, Switzerland.
PLoS Pathog ; 20(9): e1012517, 2024 Sep.
Article in En | MEDLINE | ID: mdl-39264912
ABSTRACT
The cellular prion protein, PrPC, has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrPC facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrPC. Following intracerebral inoculation with the S or NS strain, the absence of PrPC in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrPC-expressing and PrPC-lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrPC expression. Overall, these results suggest that PrPC plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alpha-Synuclein / Synucleinopathies Limits: Animals / Humans Language: En Journal: PLoS Pathog Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alpha-Synuclein / Synucleinopathies Limits: Animals / Humans Language: En Journal: PLoS Pathog Year: 2024 Document type: Article Affiliation country: Country of publication: